Syncom Formulations (India) Limited (SYNCOMF.BO)
Syncom Formulations (India) Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Indore, MP, IN. The stock last traded at $14.92, down 2.04% on the session, giving a market capitalisation of $14.05B. Its beta of 0.73 implies it has historically moved less than the broad market.
Syncom Formulations (India) Limited, established in Indore, India, in 1988, specializes in the production, distribution, and sale of a broad spectrum of pharmaceutical formulations. The company operates through three distinct segments: manufacturing and dealing in pharmaceutical drugs and formulations, trading of various commodities, and renting out properties. Its extensive pharmaceutical range addresses numerous therapeutic areas, including anti-infectives, antiparasitics, antimalarials, cardiovascular conditions, dermatology, gastroenterology, gynecology, ophthalmology, orthopedics, and pediatrics. Specific product offerings encompass treatments for anemia, lycopene, mineral and vitamin supplements, medications for vaginal pathogens, menopause, lactation insufficiency, cough suppression, liver health, urinary discomfort, and general nutritional support. These pharmaceutical products are available in multiple dosage forms, such as tablets, capsules, oral liquids, injectable solutions (vials and ampoules), dry syrups, ointments, inhalers, and herbal preparations. Furthermore, Syncom Formulations actively exports its products to international markets.
Syncom Formulations (India) Limited is most often compared with the following Healthcare names: